Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue \u00bb<\/a><\/p>\n This stands in contrast to the Phase 3 data from Agios (released in November<\/a>) with its oral pyruvate kinase activator, mitapavit, in sickle cell disease. Improving hemoglobin levels in patients with sickle cell disease helps reduce anemia and, ultimately, should reduce crisis events, including intense pain episodes.<\/p>\n In short, Novo’s etavopivat improved hemoglobin response and demonstrated a statistically significant reduction in vaso-occlusive crisis (VOC), with Novo noting that the “time to first” VOC occurred at 38.4 weeks in the treatment group compared to 20.9 weeks in the placebo group. <\/p>\n Agios trial result<\/p>\n In contrast, Agios’ mitapavit, although also improving hemoglobin response, didn’t demonstrate a statistically significant improvement in its primary endpoint of reducing “annualized rate of sickle cell pain crises (SCPCs) compared to placebo.”<\/p>\n A skeptical person. <\/p>\n Image source: Getty Images.<\/p>\n As such, the news from Novo, and its intent to file for FDA approval in the second half of 2026 is a clear threat to the earnings potential of Agios’ mitapavit, even as it works with the FDA to “achieve alignment on the confirmatory clinical trial required for submission.”<\/p>\n Clearly, Agios ‘ path to approval is longer and probably more uncertain. <\/p>\n Should you buy stock in Agios Pharmaceuticals right now?<\/p>\n Before you buy stock in Agios Pharmaceuticals, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks<\/a> for investors to buy now\u2026 and Agios Pharmaceuticals wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you\u2019d have $524,786!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,236,406!*<\/p>\n Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 994% \u2014 a market-crushing outperformance compared to 199% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n See the 10 stocks \u00bb<\/a><\/p>\n *Stock Advisor returns as of April 20, 2026. <\/p>\n Lee Samaha<\/a> has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Key Points Agios Pharmaceuticals shares dropped 23% following Novo Nordisk’s trial results. Novo’s etavopivat outperformed Agios’ mitapavit in…\n","protected":false},"author":2,"featured_media":65199,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[35827,7734,272,35828],"class_list":["post-65198","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-agios-pharmaceuticals","tag-fda-approval","tag-novo-nordisk","tag-sickle-cell"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116441701650062908","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/65198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=65198"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/65198\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/65199"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=65198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=65198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=65198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"A](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/04\/6fd044ef14e0fd11395f91211924fcef.jpeg\"\/)
<\/p>\n